© Reuters. FILE PHOTO: Pfizer vaccine photo illustration
NEW DELHI (Reuters) – Pfizer Inc (NYSE:) has applied for emergency use authorisation of its coronavirus vaccine in India, media said on Sunday, the first to do so in a country with the world’s second-highest number of infections.
The U.S. company, whose vaccine was recently approved by the British government, has written to the Drugs Controller General of India (DCGI), CNN-News18 reported citing a government source.
Officials at the DCGI and the health ministry did not respond to requests for comment. A government official, however, told Reuters that no application had been received as of Saturday night.
Pfizer could not immediately be reached.
Indian officials have said they are pinning their hopes mainly on locally tested vaccines instead of those developed by Pfizer and Moderna (NASDAQ:) Inc.
The Pfizer shot needs to be stored at minus 70 degrees Celsius (-94 F) or below, temperatures that most Indian cold storages cannot reach.
India has reported more 9.57 million COVID-19 cases, behind only the United States, with nearly 140,000 deaths.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.